propisomide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

propisomide: RN from Toxline; RN not in Chemline 8/85; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	65847
CHEMBL ID	141837
SCHEMBL ID	1649694
MeSH ID	M0133332

Synonyms (33)

Synonym
penticainide
me-3202
cm-7857
pentisomide
pentisomide [inn]
pentisomida [inn-spanish]
pentisomidum [inn-latin]
propisomide
cm 7857
me 3202
CHEMBL141837
2-[2-[di(propan-2-yl)amino]ethyl]-4-methyl-2-pyridin-2-ylpentanamide
78833-03-1
pentisomidum
alpha-(2-(diisopropylamino)ethyl)-alpha-isobutylpyridine-2-acetamide
pentisomida
unii-506t8ktw5q
506t8ktw5q ,
einecs 278-989-5
FT-0673608
pentisomide [mart.]
pentisomide [who-dd]
pentisomide [mi]
2-pyridineacetamide, .alpha.-(2-(bis(1-methylethyl)amino)ethyl)-.alpha.-(2-methylpropyl)-
(+/-)-.alpha.-(2-(diisopropylamino)ethyl)-.alpha.-isobutyl-2-pyridineacetamide
pentisomide [jan]
SCHEMBL1649694
alpha-[2-(diisopropylamino)ethyl]-alpha-isobutylpyridine-2-acetamide
AKOS030530978
cm 7857; me 3202; penticainide; pentisomide
DTXSID40869274
Q27260771
2-[[2-(diisopropylamino)ethyl]-4-methyl]-2-(2-pyridyl)pentanamide

Research Excerpts

Pharmacokinetics

Excerpt	Reference	Relevance
" Mean AUC was larger and terminal elimination half-life longer in the elderly subjects, due to a decrease in total plasma clearance of pentisomide in the elderly."	( The effect of age on the pharmacokinetics of pentisomide. Caffrey, E; Darragh, A; Holt, DW; Howse, NL; Johnston, A; Jones, RW; Walker, S, 1991)	0.28
" Its electrophysiological effects and pharmacokinetic properties were studied in 28 patients undergoing endocavitary exploration for paroxysmal supraventricular tachycardia (10 cases), WPW syndrome involving an accessory pathway (5 cases), and unexplained dizziness (13 cases)."	( Electrophysiologic effects and pharmacokinetics of intravenous penticainide (CM 7857). Aliot, E; Gagnol, JP; Gilgenkrantz, JM; Khalife, K; Munoz, A; Necciari, J, 1987)	0.27
" The pharmacokinetic parameters of penticainide including Cmax, tmax, AUC and t1/2 were not significantly altered in the presence of food."	( Influence of food and body weight on the pharmacokinetics of penticainide. Bannwarth, B; Berdaï, D; Demotes-Mainard, F; Montels, R; Necciari, J; Philip, F; Vinçon, G, 1994)	0.29

Dosage Studied

Excerpt	Relevance	Reference
" Dosage reduction, or a reduced frequency of dosing of pentisomide would be necessary in the elderly or those with impaired renal function."	( The effect of age on the pharmacokinetics of pentisomide. Caffrey, E; Darragh, A; Holt, DW; Howse, NL; Johnston, A; Jones, RW; Walker, S, 1991)	0.28

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay ID	Title	Year	Journal	Article
AID57156	Antiarrhythmic potential in conscious dogs; value ranges from +120 to +380	1983	Journal of medicinal chemistry, Mar, Volume: 26, Issue:3	Synthesis and antiarrhythmic activity of new [(dialkylamino)alkyl]pyridylacetamides.
AID63097	Intracardiac conduction in anesthetized dogs, measured as HV; HV being the conduction time in specific intraventricular tissue value ranges from +20 to +30	1983	Journal of medicinal chemistry, Mar, Volume: 26, Issue:3	Synthesis and antiarrhythmic activity of new [(dialkylamino)alkyl]pyridylacetamides.
AID63111	Intracardiac conduction in anesthetized dogs, measured as SH; SH being the atrial His bundle conduction time value ranges from +15 to +35	1983	Journal of medicinal chemistry, Mar, Volume: 26, Issue:3	Synthesis and antiarrhythmic activity of new [(dialkylamino)alkyl]pyridylacetamides.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (39)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	17 (43.59)	18.7374
1990's	21 (53.85)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (2.56)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.61

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	10.61 (24.57)
Research Supply Index	3.76 (2.92)
Research Growth Index	4.37 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (10.61)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	2 (5.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	38 (95.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
amiodarone Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.. amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.	2.38	2	0	1-benzofurans; aromatic ketone; organoiodine compound; tertiary amino compound	cardiovascular drug
disopyramide Disopyramide: A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.. disopyramide : A monocarboxylic acid amide that is butanamide substituted by a diisopropylamino group at position 4, a phenyl group at position 2 and a pyridin-2-yl group at position 2. It is used as a anti-arrhythmia drug.	5.15	11	1	monocarboxylic acid amide; pyridines; tertiary amino compound	anti-arrhythmia drug
e 4031 E 4031: class III anti-arrhythmia agent; structure given in UD	2.38	2	0	sulfonamide
flecainide Flecainide: A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.. flecainide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart).	2.67	3	0	aromatic ether; monocarboxylic acid amide; organofluorine compound; piperidines	anti-arrhythmia drug
lidocaine Lidocaine: A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.. lidocaine : The monocarboxylic acid amide resulting from the formal condensation of N,N-diethylglycine with 2,6-dimethylaniline.	2.38	2	0	benzenes; monocarboxylic acid amide; tertiary amino compound	anti-arrhythmia drug; drug allergen; environmental contaminant; local anaesthetic; xenobiotic
mexiletine Mexiletine: Antiarrhythmic agent pharmacologically similar to LIDOCAINE. It may have some anticonvulsant properties.. mexiletine : An aromatic ether which is 2,6-dimethylphenyl ether of 2-aminopropan-1-ol.	2.38	2	0	aromatic ether; primary amino compound	anti-arrhythmia drug
propafenone Propafenone: An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity.. propafenone : An aromatic ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydrochloride salt in the management of supraventricular and ventricular arrhythmias.	2.38	2	0	aromatic ketone; secondary alcohol; secondary amino compound	anti-arrhythmia drug
dpi 201-106 DPI 201-106: structure given in first source	1.97	1	0	diarylmethane
carbachol Carbachol: A slowly hydrolyzed CHOLINERGIC AGONIST that acts at both MUSCARINIC RECEPTORS and NICOTINIC RECEPTORS.	1.97	1	0	ammonium salt; carbamate ester	cardiotonic drug; miotic; muscarinic agonist; nicotinic acetylcholine receptor agonist; non-narcotic analgesic
methylene chloride Methylene Chloride: A chlorinated hydrocarbon that has been used as an inhalation anesthetic and acts as a narcotic in high concentrations. Its primary use is as a solvent in manufacturing and food technology.. dichloromethane : A member of the class of chloromethanes that is methane in which two of the hydrogens have been replaced by chlorine. A dense, non-flammible colourless liquid at room temperature (b.p. 40degreeC, d = 1.33) which is immiscible with water, it is widely used as a solvent, a paint stripper, and for the removal of caffeine from coffee and tea.	1.96	1	0	chloromethanes; volatile organic compound	carcinogenic agent; polar aprotic solvent; refrigerant
moricizine Moricizine: An antiarrhythmia agent used primarily for ventricular rhythm disturbances.. moricizine : A phenothiazine substituted on the nitrogen by a 3-(morpholin-4-yl)propanoyl group, and at position 2 by an (ethoxycarbonyl)amino group.	1.97	1	0	carbamate ester; morpholines; phenothiazines	anti-arrhythmia drug
pirmenol pirmenol: an antiarrhythmic with class Ia activity	3.07	5	0	racemate
n-methylscopolamine N-Methylscopolamine: A muscarinic antagonist used to study binding characteristics of muscarinic cholinergic receptors.	2.38	2	0
quinidine Quinidine: An optical isomer of quinine, extracted from the bark of the CHINCHONA tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular ACTION POTENTIALS, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission.. quinidine : A cinchona alkaloid consisting of cinchonine with the hydrogen at the 6-position of the quinoline ring substituted by methoxy.	2.37	2	0	cinchona alkaloid	alpha-adrenergic antagonist; anti-arrhythmia drug; antimalarial; drug allergen; EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor; EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor; muscarinic antagonist; P450 inhibitor; potassium channel blocker; sodium channel blocker
digoxin Digoxin: A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666). digoxin : A cardenolide glycoside that is digitoxin beta-hydroxylated at C-12. A cardiac glycoside extracted from the foxglove plant, Digitalis lanata, it is used to control ventricular rate in atrial fibrillation and in the management of congestive heart failure with atrial fibrillation, but the margin between toxic and therapeutic doses is small.	1.97	1	0	cardenolide glycoside; steroid saponin	anti-arrhythmia drug; cardiotonic drug; EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; epitope
tetrodotoxin Tetrodotoxin: An aminoperhydroquinazoline poison found mainly in the liver and ovaries of fishes in the order TETRAODONTIFORMES, which are eaten. The toxin causes paresthesia and paralysis through interference with neuromuscular conduction.. tetrodotoxin : A quinazoline alkaloid that is a marine toxin isolated from fish such as puffer fish. It has been shown to exhibit potential neutotoxicity due to its ability to block voltage-gated sodium channels.	1.97	1	0	azatetracycloalkane; oxatetracycloalkane; quinazoline alkaloid	animal metabolite; bacterial metabolite; marine metabolite; neurotoxin; voltage-gated sodium channel blocker
bisaramil [no description available]	2.43	2	0
piperidines Piperidines: A family of hexahydropyridines.	3.23	6	0

Condition	Relationship Strength	Studies	Trials
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	1.98	1	0
Arrhythmia [description not available]	3.07	5	0
Arrhythmias, Cardiac Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction.	3.07	5	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	1.98	1	0
Injury, Myocardial Reperfusion [description not available]	1.98	1	0
Heart Disease, Ischemic [description not available]	1.98	1	0
Myocardial Ischemia A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).	1.98	1	0
A-V Dissociation [description not available]	1.98	1	0
Sick Sinus Node Syndrome [description not available]	1.98	1	0
Atrioventricular Nodal Reentrant Tachycardia [description not available]	2.38	2	0
Tachycardia, Supraventricular A generic expression for any tachycardia that originates above the BUNDLE OF HIS.	2.38	2	0
Cardiac Complex, Premature [description not available]	3.36	1	1
Auricular Flutter [description not available]	1.97	1	0
Atrial Flutter Rapid, irregular atrial contractions caused by a block of electrical impulse conduction in the right atrium and a reentrant wave front traveling up the inter-atrial septum and down the right atrial free wall or vice versa. Unlike ATRIAL FIBRILLATION which is caused by abnormal impulse generation, typical atrial flutter is caused by abnormal impulse conduction. As in atrial fibrillation, patients with atrial flutter cannot effectively pump blood into the lower chambers of the heart (HEART VENTRICLES).	1.97	1	0
Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.	1.97	1	0
Muscle Contraction A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.	1.97	1	0
Anomalous Ventricular Excitation Syndrome [description not available]	1.97	1	0
Wolff-Parkinson-White Syndrome A form of ventricular pre-excitation characterized by a short PR interval and a long QRS interval with a delta wave. In this syndrome, atrial impulses are abnormally conducted to the HEART VENTRICLES via an ACCESSORY CONDUCTING PATHWAY that is located between the wall of the right or left atria and the ventricles, also known as a BUNDLE OF KENT. The inherited form can be caused by mutation of PRKAG2 gene encoding a gamma-2 regulatory subunit of AMP-activated protein kinase.	1.97	1	0
Tachyarrhythmia [description not available]	2.37	2	0
Tachycardia Abnormally rapid heartbeat, usually with a HEART RATE above 100 beats per minute for adults. Tachycardia accompanied by disturbance in the cardiac depolarization (cardiac arrhythmia) is called tachyarrhythmia.	2.37	2	0
Chronic Illness [description not available]	1.97	1	0
Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).	1.97	1	0

chemdatabank.com